Article info
PDFShort report
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
- Correspondence to Dr Tomás Palanques-Pastor, Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia 46026, Spain; palanques_tom{at}gva.es
Citation
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Publication history
- Received April 21, 2020
- Revised May 9, 2020
- Accepted May 12, 2020
- First published June 4, 2020.
Online issue publication
November 23, 2020
Article Versions
- Previous version (24 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage